MDGEF Stock News Medigene Ag (MDGEF) 7.1400 07/26/2014 16:00

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medigene Ag (MDGEF) 7.1400 $MDGEF

Global Metastatic Adenocarcinoma of The Pancreas Therapeutics Pipeline Report H1 2014 - 13 Companies & 18 Drug Profiles
M2 - Tue May 20, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jp2nvl/metastatic) has announced the addition of the "Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Adenocarcinoma of The Pancreas and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Gilead Sciences, Inc. - MediGene AG - Nanotherapeutics, Inc. - Novartis AG - Aduro BioTech, Inc. - Halozyme Therapeutics, Inc. - Oncolytics Biotech Inc. - Peregrine Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Axcentua Pharmaceuticals AB - BioCancell Therapeutics, Inc. - NewLink Genetics Corporation - Eleison Pharmaceuticals, Inc. Drug Profiles - glufosfamide - TH-302 - MEK-162 - pelareorep - BC-819 - paclitaxel lipsomal - Triapine - luminespib - CRS-207 - simtuzumab - PEGPH-20 - AXP-10711 - erismodegib - indoximod - Stem Cell Therapy for Metastatic Adenocarcinomas - siG-12D LODER - PRI-724 - Anti-Angiogenesis Agent 2C3 For more information visit http://www.researchandmarkets.com/research/jp2nvl/metastatic

Global Gliosarcoma Clinical Trials Review, H2, 2013
M2 - Mon Jan 13, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxpcs7/gliosarcoma) has announced the addition of the "Gliosarcoma Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Gliosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gliosarcoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Gliosarcoma Therapeutics Clinical Trials - Actelion Ltd - Arno Therapeutics, Inc. - Biogen Idec Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - DNAtrix, Inc. - Eli Lilly and Company - Exelixis, Inc. - MediGene AG - Merck & Co., Inc. For more information visit http://www.researchandmarkets.com/research/kx...liosarcoma

Genital Warts Global Clinical Trials Review, H2, 2013 Includes Players such as Helix Therapeutics LLC and MediGene AG
M2 - Thu Jan 09, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttmvbz/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2013" provides data on the Genital Warts (Condylomata Acuminata) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Warts (Condylomata Acuminata). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Warts (Condylomata Acuminata). Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Anaconda Pharma -BioMAS Ltd. -Clinical Trial Overview of Helix Therapeutics LLC -Department of Biotechnology, India -G&E Herbal Biotechnology Co., Ltd. -Gilead Sciences, Inc. -Graceway Pharmaceuticals, LLC -Helix Therapeutics LLC -Huazhong University of Science & Technology -Karolinska Institutet -Medical Research Council -MediGene AG -Merck & Co., Inc. -The University of British Columbia -The University of Queensland -Universidad de Valparaiso -University of California, Los Angeles For more information visit http://www.researchandmarkets.com/research/tt...ital_warts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid

Warts - Pipeline Review, H2 2012
M2 - Tue Jan 22, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g637jc/warts_pipeline) has announced the addition of Global Markets Direct's new report "Warts - Pipeline Review, H2 2012" to their offering. 'Warts - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Warts, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Warts. Scope - A snapshot of the global therapeutic scenario for Warts. - A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Warts pipel
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 21

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 66

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 150

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 7

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 135

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 38

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 180

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 65

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 110

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading

Top 5 Most Recently Viewed Articles

Pharvaris Shares Promising Data on Deucrictibant Efficacy

Updated Category News Views 186

Pharvaris Highlights Clinical Progress in HAE Treatment At the recent AAAAI/WAO Joint Congress, Pharvaris presented compelling long-term clinical data supporting the use of deucrictibant, a novel oral treatment for hereditary angioedema (HAE). This data underscores the drug's potential to not only prevent but also effectively address HAE attacks, offering hope to those...

Continue Reading
First Horizon Opens New Banking Center Celebrating Local Pride

Updated Category News Views 349

First Horizon Unveils New Banking Center with Appalachian Spirit First Horizon Bank (NYSE: FHN) proudly celebrated the grand opening of its newly refreshed banking center. The location pays tribute to the vibrant Appalachian State community, showcasing a striking theme that reflects its strong ties with Appalachian State University and its athletics. This celebration...

Continue Reading
Understanding Namodenoson's Role in Liver Cancer and Beyond

Updated Category News Views 243

Innovative Research on Namodenoson’s Impact in Liver Cancer Therapy Namodenoson, developed by Can-Fite BioPharma Ltd., is making waves in the medical community as a promising candidate for liver cancer treatment. Unlike traditional chemotherapy, which often harms healthy cells, Namodenoson is lauded for its protective qualities towards normal body systems. Published...

Continue Reading
Geotab Enhances Public Sector Solutions with Technological Advancements

Updated Category News Views 147

Geotab Enhances Public Sector Solutions with Technological Advancements Geotab Inc., a leader in connected vehicle solutions and asset management, has taken a major step forward in serving the public sector by expanding its cooperative purchasing contracts with Sourcewell and Canoe Procurement Group. This expansion introduces four cutting-edge solutions aimed at enhancing...

Continue Reading
Dun & Bradstreet Earns TRUSTe Certification for Responsible AI

Updated Category News Views 351

Dun & Bradstreet Achieves TRUSTe Responsible AI Certification Dun & Bradstreet (NYSE:DNB), recognized globally as a leading provider of business decisioning data and analytics, has been awarded the TRUSTe Responsible AI Certification. This certification signifies the company’s commitment to ethical and responsible governance in the realm of artificial intelligence (AI)....

Continue Reading